The effect of 8 weeks treatment with the calcium antagonist felodipine on blood pressure, heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and aldosterone in patients with essential hypertension.

Pl, Katzman; Hulthén, U L; Hökfelt, Bernt

doi:10.1111/j.1365-2125.1986.tb05227.x

Cited by 25 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have demonstrated the efficacy of felodipine in essential hypertension (Andersson et al 1985;Katzman et al 1986;Saltiel et al 1988;Smith et al 1986). A double-blind, placebo-controlled study in patients with hypertension revealed that long term administration of felodipine resulted in a reduction of blood pressure despite increased levels of norepinephrine (noradrenaline), epinephrine (adrenaline) and angiotensin-II.…”

Section: Hypertensionmentioning

confidence: 96%

Felodipine Clinical Pharmacokinetics

Dunselman

Edgar

1991

Clinical Pharmacokinetics

View full text Add to dashboard Cite

Absorption of felodipine is rapid and complete. A pronounced first-pass metabolism results in a bioavailability of 15%, irrespective of the oral formulation used. The peak plasma concentrations and area under the plasma concentration-time curve are linearly related to the dose. The variability in plasma concentrations is wide, and individualization of the dosage is recommended. Plasma felodipine concentrations are increased in the elderly, and in patients with congestive heart failure or liver cirrhosis; in these patients felodipine should be started at a low dosage. Food intake has no clinically significant effect on felodipine absorption. Serum digoxin concentrations are increased by felodipine in plain tablet form, but not when it is administered as extended release tablets. Activators, inducers and inhibitors of the cytochrome P450 system affect the plasma concentrations of felodipine. No displacement reactions with high affinity protein binding drugs have been observed. There is a significant correlation between plasma concentration and haemodynamic effect. The mean elimination half-life of 24h together with the extended release formulation of felodipine favours once-daily dosage in patients with hypertension.

show abstract

Section: Hypertensionmentioning

confidence: 96%

Felodipine Clinical Pharmacokinetics

Dunselman

Edgar

1991

Clinical Pharmacokinetics

View full text Add to dashboard Cite

show abstract

“…Felodipine, a new 1,4 dihydropyridine derivative with calcium-channel blocking activity, has been found to be a very selective dilator of smooth muscle in small blood vessels (Ljung, 1985;Nordlander et al, 1986) and to also have a diuretic effect (Edgar et al, 1985a;Katzman et al, 1986). Consequently, this compound is effective in reducing high blood pressure in hypertensive patients.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of felodipine in patients with impaired renal function.

Edgar

Regårdh

et al. 1989

Brit J Clinical Pharma

View full text Add to dashboard Cite

1. The pharmacokinetics of felodipine and its effects on blood pressure and heart rate were studied in eight male patients aged between 28 and 57 years with a glomerular filtration rate, GFR, between 8 and 68 ml min‐1, following single i.v. and oral administration. 2. Clearance, Cmax, AUC, Vss and V, of felodipine were unaffected by the renal disease. The metabolite excretion (14C‐labelled) was slower than in healthy subjects. Initial renal clearance of these metabolites correlated with individual GFR values. The total amount of the dose excreted in the urine was also decreased.

show abstract

“…Felodipine is a dihydropyridine calcium antagonist with a potent acute and long-term antihypertensive effect (Andersson et al 1984;Mace et al 1985;Katzman et al 1986). …”

mentioning

confidence: 99%

Glucoregulatory hormone response to insulin-induced hypoglycaemia following long-term calcium antagonism with felodipine in patients with essential hypertension

Hökfelt

1987

Acta Endocrinologica

View full text Add to dashboard Cite

The effect of 8 weeks' treatment with the dihydropyridine calcium antagonist felodipine on glucoregulatory hormone response following insulin\x=req-\ induced hypoglycaemia was evaluated in 7 patients with essential hypertension, WHO grade I\p=n-\II.After an iv insulin injection (0.1 IU/kg), blood glucose decrement and nadir were similar before and during felodipine treatment. Basal glucagon, noradrenaline, adrenaline, GH and cortisol levels were unchanged, and the response to insulin-induced hypoglycaemia was similar before and during felodipine treatment. Basal plasma dopamine levels were similar and did not change during insulin-induced hypoglycaemia before and during felodipine treatment. Basal serum levels of TSH, T3 and T4 were unaltered following felodipine. In conclusion, long-term treatment with felodipine did not alter the hypoglycaemic effect of exogenous insulin, or the recovery from hypoglycaemia or the glucoregulatory hormone response to insulin-induced hypoglycaemia in patients with essential hypertension.

show abstract

The effect of 8 weeks treatment with the calcium antagonist felodipine on blood pressure, heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and aldosterone in patients with essential hypertension.

Cited by 25 publications

References 30 publications

Felodipine Clinical Pharmacokinetics

Felodipine Clinical Pharmacokinetics

Pharmacokinetics of felodipine in patients with impaired renal function.

Glucoregulatory hormone response to insulin-induced hypoglycaemia following long-term calcium antagonism with felodipine in patients with essential hypertension

Contact Info

Product

Resources

About